Clinical Trial Update: Journey Study: Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as Adjunctive Treatment for Schizophrenia [Phase 3]

View source ↗

Summary

Phase 3 Journey Study results completed evaluating valbenazine as an adjunctive treatment for schizophrenia to assess its efficacy, safety, and tolerability.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• INGREZZA (valbenazine)

Snippet

Sponsor: Neurocrine Biosciences | Conditions: Schizophrenia | Phase 3 | Status: COMPLETED